NFKB1 and glaucoma: Previous preclinical and clinical studies have suggested that the NF-κB pathway has an anti-inflammatory effect on inflammatory diseases, including dry eye syndrome and glaucoma [55, 56], which further affirms the potential clinical value of DMHCA for the treatment of glaucoma.